Dialogue with a CAR-T Pioneer | Prof. Pei Shanshan and Prof. Michel Sadelain Jointly Depict the Origin, Evolution, and Future Journey of Cellular Therapy
As a revolutionary technology selected among the “Top 10 Global Engineering Achievements of 2024,” CAR-T therapy marks the arrival of the cellular therapy era and brings transformative possibilities to the treatment of cancer and major diseases. During the 2025 International Conference on Cellular and Immune Therapy, a deep dialogue between Prof. Pei Shanshan from Liangzhu Laboratory and the First Affiliated Hospital of Zhejiang University School of Medicine, and Prof. Michel Sadelain, a founding pioneer in the CAR-T field and Director of the Columbia Initiative in Cell Engineering and Therapy (CICET), offered a panoramic exploration of this frontier field. From the pioneering conceptual origins of cellular therapy, to the precise selection of the CD19 target, to more than two decades of persistence behind clinical breakthroughs, and further to the expansion toward autoimmune diseases, the dialogue advanced step by step. It revisited the evolution of the technology from “an impossible idea” to clinical success, directly addressed core challenges such as cancer heterogeneity and treatment cost, and looked ahead to next-generation technologies such as in vivo CAR-T. Hematology Frontier – Blood News hascompiled the full content to present a systematic overview of the past, present, and future of CAR-T therapy.
CCHIO 2025丨Professor Tang Feifei: Diagnostic Challenges and Future Breakthroughs in Therapy-Related Myeloid Neoplasms
From November 6–9, 2025, the 2025 China Conference on Holistic Integrative Oncology (CCHIO) was held in Kunming. As one of the most influential oncology conferences in China, CCHIO gathered leading…
Dr. Yishan Ye: Advancing Haploidentical Transplantation — Toward “Timely Access to Optimal Donors for All” | ICIC 2025
To promote innovation in China’s cell therapy and immunotherapy fields, advance discussion of key scientific challenges, share the latest clinical research, and strengthen global collaboration and translational progress, the 2025…
Prof. Tak W. Mak: The Multifaceted Challenges and Collaborative Innovation in TCR Clinical Translation—From Target Selection to Combination Strategies | CTI 2025
To advance innovation in China’s cell and immunotherapy landscape, deepen exchanges on key scientific questions, and share the latest clinical research progress, the 2025 International Cell and Immunotherapy Conference (CTI 2025)—jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Society of Immunology, and the Zhejiang Anti-Cancer Association, and co-hosted by the First Affiliated Hospital of Zhejiang University School of Medicine and the Liangzhu Laboratory—was held in Hangzhou, Zhejiang, from November 13 to 16, 2025.